Analysts Are Bullish on Top NA Stocks: Viking Holdings Ltd (VIK), CG Oncology, Inc. (CGON)

TipRanksMay 28 06:23 ET

Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo

Seeking AlphaMay 25 10:24 ET

Sector Update: Health Care Stocks Softer in Friday Afternoon Trading

Health care stocks were easing Friday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.1%. The iShares Biotechnology ETF (IBB) rose 0

MT NewswiresMay 24 14:02 ET

CG Oncology Says Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint

CG Oncology (CGON) said Friday that its phase 2 trial of cretostimogene plus pembrolizumab to treat BCG-unresponsive high-risk non-muscle invasive bladder cancer with carcinoma in situ met its primary

MT NewswiresMay 24 09:58 ET

Express News | CG Oncology To Present Final Results From Phase 2 CORE-001 Study Of Cretostimogene Grenadenorepvec In Combination With Pembrolizumab In BCG-Unresponsive High-Risk NMIBC At ASCO 2024 Annual Meeting

BenzingaMay 24 08:08 ET

CG Oncology to Present Positive Final Results From Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination With Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

CG Oncology, Inc. (NASDAQ: CGON) today announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS).

GlobeNewswireMay 24 08:00 ET